Search This Blog

Friday, November 20, 2026

FDA CRL rejecting deramiocel on data integrity sinks Capricor 70% after hours

 


  • FDA posted Nov. 20 statement issuing a complete response letter for the deramiocel BLA.
  • Agency said HOPE-3 data are unreliable due to serious integrity violations that cannot be fixed.
  • BIMO inspection found unauthorized SAP changes, blinding breaches and other protocol issues.
  • Evidence failed the approval standard even after the major amendment and July AdCom.
  • PDUFA target was Nov. 22; FDA released the decision early on Friday after the close.
  • Regular session closed +0.8% at about $7.59 before the after-hours collapse to $2.29.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.